BiotechTube
HilleVax

HilleVax

HLVX
Boston, United States· Est.
hillevax.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Overview

HilleVax is a clinical-stage biotech focused on developing and commercializing novel vaccines, with a lead program targeting norovirus-induced acute gastroenteritis. The company's core asset, HIL-214, is advancing through Phase 2b/3 and Phase 2 trials, aiming to address a large, underserved global market. Founded by former Takeda Vaccines leaders, HilleVax's strategy hinges on leveraging its team's proven expertise in vaccine development and commercialization. As a pre-revenue public company, its near-term value is tied to the clinical and regulatory success of HIL-214.

Infectious DiseaseGastroenterology

Technology Platform

Recombinant virus-like particle (VLP) platform for vaccine development, utilizing non-infectious particles that mimic viral structure to induce strong immune responses.

Pipeline

4
4 drugs in pipeline2 in Phase 3
DrugIndicationStageWatch
HIL-214 + PlaceboGastroenteritisPhase 2/3
HIL-214 + PlaceboGastroenteritisPhase 2/3
HIL-214GastroenteritisPhase 2
Placebo + HIL-214GastroenteritisPhase 1

Opportunities

First-in-class norovirus vaccine targeting a massive, unaddressed global market with no approved therapies.
Successful Phase 2b/3 data could trigger lucrative partnership deals with major pharma and pave a clear regulatory path to a multi-billion dollar market.

Risk Factors

Extreme binary risk as company value is tied to a single clinical asset (HIL-214).
Clinical trial failure would be catastrophic.
Significant future capital needs will likely lead to shareholder dilution.
Faces emerging competition and complex commercialization challenges.

Competitive Landscape

HilleVax's HIL-214 is the most advanced candidate in clinical development. Primary competitors include Vaxart (oral Phase 1b candidate) and Beijing Wantai (Phase 2 in China). The experienced team and advanced stage provide a competitive edge, but larger pharma entry remains a threat.

More companies in Biologics / Biosimilars →More companies in United States →